Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23959359 | 0.83 | KDM4E (0.43) | KEAP1NFE2L2KDM4EALOX15TSHR | |
| SCHEMBL24174302 | 0.83 | KDM4E (0.43) | KEAP1NFE2L2KDM4EALOX15TSHR | |
| SCHEMBL30422185 | 0.83 | KDM4E (0.43) | KEAP1NFE2L2KDM4EALOX15TSHR | |
| SCHEMBL30952112 | 0.82 | PRCP (0.52) | PRCPSLC22A1KEAP1NFE2L2OPRM1 | |
| SCHEMBL9913091 | 0.82 | PRCP (0.52) | PRCPSLC22A1KEAP1NFE2L2OPRM1 | |
| SCHEMBL14933933 | 0.82 | PRCP (0.52) | PRCPSLC22A1KEAP1NFE2L2OPRM1 | |
| SCHEMBL24175264 | 0.77 | KDM4E (0.40) | KEAP1NFE2L2OPRM1KDM4ESMN1; SMN2 | |
| SCHEMBL23959358 | 0.77 | KDM4E (0.40) | KEAP1NFE2L2OPRM1KDM4ESMN1; SMN2 | |
| SCHEMBL30422426 | 0.77 | KDM4E (0.40) | KEAP1NFE2L2OPRM1KDM4ESMN1; SMN2 | |
| SCHEMBL25264952 | 0.76 | KDM4E (0.39) | KEAP1NFE2L2KDM4EALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | PRCP 2778/4885SLC22A1 2616/4885KEAP1 1/4885 |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | KEAP1, NFE2L2, HMOX1 | PRCP 2778/4885SLC22A1 2616/4885KEAP1 1/4885 |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | PRCP 2778/4885SLC22A1 2616/4885KEAP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.